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Key messages
 ► Development of male hormonal 
contraception has been delayed by 
multiple factors, but new clinical trials 
are closer than ever to bringing viable 
products to market.
 ► With new technologies, new potential 
non-hormonal targets for male 
contraception have been discovered.
 ► Developing a greater range of male 
methods is vital to providing holistic 
reproductive healthcare.
AbstrAct
Progress in developing new reversible male 
contraception has been slow. While the 
hormonal approach has been clearly shown 
to be capable of providing effective and 
reversible contraception, there remains no 
product available. Currently, trials of a self-
administered gel combination of testosterone 
and the progestogen Nestorone® are under 
way, complementing the largely injectable 
methods previously investigated. Novel long-
acting steroids with both androgenic and 
progestogenic activity are also in early clinical 
trials. The non-hormonal approach offers 
potential advantages, with potential sites 
of action on spermatogenesis, and sperm 
maturation in the epididymis or at the vas, but 
remains in preclinical testing. Surveys indicate the 
willingness of men, and their partners, to use a 
new male method, but they continue to lack that 
opportunity.
IntroductIon
The Faculty of Sexual and Reproduc-
tive Healthcare vision statement1 focuses 
on patient experience, specifically that 
patients should have access to the full range 
of contraceptive options. For men, these 
options are currently limited to condoms 
and vasectomy. Both these methods have 
their positives—condoms continue to 
play a vital role in infection prevention 
and are a widely used, easily accessible 
method of contraception; likewise, vasec-
tomy is a highly effective permanent 
method of contraception. However, they 
are not sufficient for many sexually active 
men who wish to have control over their 
fertility, and for their partners who wish 
to share the burden of contraception. We 
know that sterilisation and condoms are 
not sufficient for women to control their 
fertility, and having a greater breadth of 
contraceptive tools allows more couples 
to have better reproductive control. This 
review will help clinicians to understand 
the male contraceptives that are on the 
horizon and may start coming to market 
in the medium term.
the lIfe course of A sperm
Spermatogenesis begins in the brain. 
The hypothalamus secretes gonadotro-
phin-releasing hormone (GnRH), which 
in turn stimulates the anterior pituitary 
to release luteinising hormone (LH) and 
follicle stimulating hormone (FSH). These 
hormones then act on the Leydig and 
Sertoli cells within the testis.
Leydig cells produce testosterone, 
which is secreted into the bloodstream. 
Serum testosterone supports a wide range 
of male functions and is a key compo-
nent of the negative feedback loop that 
controls GnRH and gonadotrophin 
production. Testicular levels of testos-
terone are approximately 40 times higher 
than in blood2 and support Sertoli cells in 
their role in spermatogenesis.
After release from Sertoli cells (‘spermi-
ation’), sperm progress through the semi-
niferous tubules and into the epididymis 
for storage, concentration and maturation 
to functional sperm. Finally, at the point 
of ejaculation, sperm are transferred 
from the epididymis via the vas deferens 
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Figure 1 The hypothalamic-pituitary-testicular axis and its role in 
spermatogenesis. CCBY 4.0 Licence – John Reynolds-Wright. Image 
accessible via https://flic.kr/p/2hgvk5V6A. FSH, follicle stimulating 
hormone; GnRH, gonadotrophin-releasing hormone; LH, luteinising 
hormone.
Potential novel male contraceptives can be divided 
into those based on a hormonal approach, acting 
via gonadotrophin suppression, and non-hormonal 
methods. Hormonal strategies for male contracep-
tion involve the hypothalamic-pituitary-testicular 
(HPT) axis, using exogenous testosterone in combina-
tion with progestogen to drive the negative feedback 
response and suppress GnRH, FSH and LH. Exoge-
nous replacement of testosterone prevents hypogo-
nadal side effects from HPT axis suppression but is not 
delivered at high enough concentrations to support 
spermatogenesis directly. Non-hormonal methods can 
act at any point during spermatogenesis or can target 
sperm maturation, detachment, motility or transport 
out of the testis. This includes physical methods of 
infiltration of the vas with a dissolvable compound to 
block or damage sperm during their movement along 
the vas.
A brIef hIstory of hormonAl mAle 
contrAceptIon
The question asked most frequently about male contra-
ception, other than ‘When will it be ready?’, is ‘what 
is taking so long?’. The following summary on the 
history of male contraception will hopefully answer 
this question.
The quest to develop new forms of male contracep-
tion started at more or less the same time as the devel-
opment of female hormonal contraceptive methods, 
but has taken a very different course. The culture shift 
that took place in the wake of the phenomenon of 
the hormonal contraceptive pill for women3 in 1965 
led to the creation of the WHO Special Programme 
of Research, Development and Research Training 
in Human Reproduction (WHO-HRP).3 Within the 
WHO-HRP a task force for developing methods of 
male fertility regulation was developed. This iden-
tified possible modalities for male contraceptives 
through basic science research projects and multi-
centre landmark clinical trials of testosterone alone 
and in combination with progestogens.3 The task force 
also focused efforts on the development and promo-
tion of no-scalpel vasectomy, which has become the 
predominant technique globally, and gossypol, which 
was planned as a reversible contraceptive but unfortu-
nately had to be abandoned due to issues with toxicity 
and irreversibility.3
Over approximately a decade from the mid-1980s, 
the task force developed new esters of testosterone 
with the hope that they would be developed by 
industry partners for use in treatment of hypogo-
nadal patients and as male contraceptives. However, 
this did not come to fruition, for reasons including 
concerns in industry about security of patents, possi-
bility of litigation, perception of a ‘small market’ and 
competition with their existing female contraceptives. 
Nevertheless, landmark contraceptive efficacy studies 
were conducted at this time using weekly injections of 
testosterone enanthate. The first of these demonstrated 
that most men (70%) became azoospermic when 
administered 200 mg/week of testosterone enanthate, 
and couples then used this as their exclusive method 
of contraception for 12 months. This proved to be a 
highly effective contraceptive, with only 0.8 pregnan-
cies per 100 person-years of exposure.4 A second study 
extended this to ask ‘how low does a sperm count 
need to go?’, and used 3 million/mL as the cut-off for 
entry to the efficacy phase. This increased the response 
rate (92% of men achieved sperm counts below this 
threshold and entered the efficacy phase), and again 
excellent efficacy was demonstrated with a Pearl Index 
of 1.4 (95% CI 0.4 to 3.7).5 Although a Pearl Index 
of 8.1 (95% CI 2.2 to 20.7) was achieved even in 
men who were not azoospermic, it was subsequently 
decided that <1 million/mL was the appropriate sperm 
count cut-off for future contraceptive efficacy studies.6
While these studies demonstrated that hormonal 
contraception using testosterone was a real possi-
bility for men, subsequent studies have focused on 
a combination with progestogens, which are potent 
gonadotrophin suppressors in men as they are in 
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dose of testosterone to be used, essentially using the 
progestogen to do the gonadotrophin suppression, 
with approximately physiological doses of testos-
terone providing replacement for the suppressed 
Leydig cell function. The 1990s saw a lot of activity 
exploring a range of progestogens, although generally 
in small studies with spermatogenic suppression as the 
end point, rather than contraceptive efficacy.7 A key 
limitation at that time was the absence of a long-acting 
testosterone preparation, although testosterone pellets 
were used in studies, predominantly in the UK and 
Australia. In prototype long-acting reversible contra-
ceptive (LARC) studies, testosterone pellets were 
combined with etonogestrel implants, showing excel-
lent spermatogenic suppression,8 and in combination 
with depot medoxyprogesterone acetate (DMPA) were 
used in an efficacy study, with no pregnancies in 55 
couples over 35.5 person-years of exposure.9
The development of long-acting testosterone unde-
canoate (TU) by Schering led to a collaborative study 
with Organon, which developed specific etonoges-
trel implants for men for a trial of that combination, 
confirming effective spermatogenic suppression.10 
Unfortunately, this industry involvement was short-
lived due to changing priorities in both companies, 
and there are no commercially funded active studies 
at present. In China, large studies were also conducted 
using TU alone.11 The combination approach was devel-
oped into an efficacy study by WHO and CONRAD 
(Contraception Research and Development network), 
using TU with norethisterone enanthate, both given 
at 8-week intervals (with the anticipation of a single 
combination injection being developed). This study 
recruited over 300 couples internationally, with 96.8% 
of men achieving sufficient spermatogenic suppression 
to enter the 1-year efficacy phase. While the trial was 
stopped early by a WHO review panel due to concern 
over side effects (despite very few men discontinuing 
treatment), there were just four pregnancies, giving a 
contraceptive efficacy of 1.59% (CI 0.6 to 4.2),12 thus 
matching hormonal female methods and substantially 
better than condoms, the only current reversible male 
method.
The essential role of GnRH in regulating reproduc-
tive function makes it an obvious target for study, since 
the early days of development of GnRH agonists in 
reproductive medicine. Both agonists and antagonists 
have the potential to act as contraceptives. GnRH 
agonists do not result in sufficient gonadotrophin 
suppression in men, but GnRH antagonists are very 
effective and there have been several studies that have 
investigated GnRH antagonists (with testosterone); 
however, these did not reduce sperm concentrations 
to a greater degree than testosterone-progestogen 
combinations.13 GnRH antagonists have only been 
available in parenteral preparations requiring serial 
injections or infusions, which have practicality and 
cost implications. New oral GnRH antagonists are 
becoming available, developed for the treatment of 
endometriosis,14 and may have a role to play as part of 
a patient-controlled contraceptive in the future.
current And future hormonAl 
ApproAches
testosterone and nestorone® (segesterone acetate) 
transdermal gel
A nestorone-testosterone gel (NES/T) has recently 
entered an international phase IIb clinical trial to estab-
lish efficacy and side effect frequency, supported by 
the US National Institute of Child Health and Human 
Development and the Population Council. Nesto-
rone® is a novel potent progestogen with minimal 
activity at the androgen receptor, also licensed by the 
Food and Drug Administration as a combined vaginal 
ring for female contraception, not yet available in the 
UK. This is a patient-controlled, daily-dose method of 
combined progestogen-testosterone hormonal contra-
ception. Minimal side effects are anticipated due to the 
relatively low dose of testosterone and progestogen 
delivered.15
In the development of this approach, NES/T was 
shown to suppress FSH and LH to less than 1 IU/L (a 
level consistent with achieving contraceptive effective-
ness in other trials) more consistently and effectively 
than testosterone gel alone. There was a significant 
decrease in sperm concentrations in the NES/T group 
despite the duration of treatment being only 4 weeks, 
and no differences in psychosexual measures between 
groups or from baseline.16
Kisspeptin-based hpt suppression
Kisspeptin is a compound recently discovered to play 
a significant role in the regulation of GnRH release 
by the hypothalamus. The kisspeptin-neurokinin 
B-dynorphin pathway acts on the hypothalamus to 
upregulate and downregulate the release of GnRH.17 
It has potential to be used both in patients with hypo-
gonadism to increase GnRH and sex steroid produc-
tion, and conversely to suppress GnRH production 
and thus the HPT axis as a potential contraceptive,18 
but we are not aware of any current trials related to 
male contraception.
synthetic androgen-progestogen compounds and 
selective androgen receptor modulators
Several chemical compounds have been developed that 
exhibit both androgenic and progestogenic effects and 
represent potential male contraceptives, combining 
both aspects of what is currently the leading hormonal 
approach and might also be useful for hypogonadism. 
There are various ongoing studies to develop these 
drugs, both as implantable and oral contraceptives. 
Recently, phase I trials of two oral preparations, 
11-beta-methyl-19-nortestosterone dodecylcar-
bonate19 and dimethandrolone undecanoate,20 have 
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and therefore promise as potential male contraceptive 
pills, although at a very early stage.
7alpha-methyl-19-nortestosterone (MENT) is a 
potent androgen which does not undergo 5-alpha 
reduction but is aromatised; this combination may 
even allow protective effects against prostate disease, 
while supporting sexual function and bone density.21 
When administered as an implant (because of rapid 
clearance), MENT can provide good gonadotrophin 
and spermatogenic suppression.22
non-hormonAl ApproAches ActIng on 
spermAtogenesIs
bisdichloroacetyldiamines
Conversion of vitamin A to retinoic acid in the testis is 
essential for spermatogenesis, as retinoic acid is essen-
tial for initiation of meiosis. Meiosis is a potentially 
attractive target for contraception, as its only function 
is the production of haploid gametes; thus, sufficient 
specificity should reduce the likelihood of off-target 
effects and not interfere with the endocrine function 
of the testis. Conversion from vitamin A is mediated 
by alcohol and aldehyde dehydrogenases, which can 
be reversibly inhibited by administration of bisdichlo-
roacetyldiamines. To date this has been successfully 
used to induce azoospermia in rabbits, which reversed 
following withdrawal of the compound, but unfortu-
nately in humans the drug induces an ‘antabuse’-type 
reaction. Further studies, including the development 
of agents without this side effect, are warranted as the 
method may induce azoospermia more rapidly than 
hormonal methods.23
bromodomain testis-specific protein inhibitors
Bromodomain testis-specific proteins (BRDTs) are 
expressed during the development of maturing sper-
matocytes and are important in the remodelling of 
cellular chromatin. A BRDT inhibitor has been shown 
to induce reversible infertility in mice without affecting 
serum testosterone levels or copulatory behaviour.24 
Further development from this important proof of 
concept may be facilitated by the potential of related 
drugs in oncology.
lonidamine derivatives
Lonidamine was discovered in the 1970s and is a 
non-hormonal drug that is known to have antispermat-
ogenic characteristics; however, it also had significant 
side effects, including testicular pain and liver dysfunc-
tion. Derivatives of lonidamine, including adjudin 
and gamendazole, have fewer side effects and act by 
causing premature detachment of spermatids from 
the Sertoli cells and subsequent infertility.25 Unfortu-
nately, in animal studies, doses that could give effective 
contraception either resulted in liver side effects or 
irreversibility. However, further studies are in progress 
to modify these compounds to improve reversibility 
and reduce adverse effects.26
thermal treatment
Transient mild increases in testicular temperature can 
result in reduction in sperm count particularly when 
paired with a hormone administration, but is infe-
rior to combined testosterone and progestogen treat-
ment.27 There are some small communities of men 
practising ‘do-it-yourself ’ thermal treatments, either 
using a hot bath method or with a modified form of 
underwear to create ‘artificial cryptorchidism’. There 
is not much current active research; however, a recent 
French acceptability study reported that one-third 
of respondents showed interest in this method as a 
contraceptive.28
non-hormonAl ApproAches ActIng on the 
epIdIdymIs
The epididymis is responsible for concentrating sperm 
within the seminiferous fluid and conditioning the 
lipids and proteins on the surface of the sperm. This 
process takes several weeks and is essential for matura-
tion of the sperm to improve their functionality. There 
are several areas currently being explored as potential 
sites of intervention for a male contraceptive. There 
are proteins, for example Eppin,29 expressed in the 
epididymis (and nowhere else in the body) that could 
be targeted with drugs that disrupt their functions. As 
these proteins are only expressed in the reproductive 
tract, there should theoretically be few side effects to 
these methods.29
non-hormonAl ApproAches ActIng on the 
vAs
Intravasal agents
The reversible inhibition of sperm under guidance 
technique involves the injection of a polymer into the 
vas, which then acts to destabilise the cell membrane 
of sperm that pass through it, rendering them non-vi-
able. As there is not a complete barrier to fluid passage 
along the vas, issues relating to back-pressure are 
avoided. The method can later be reversed either 
by mechanically massaging the polymerised section 
of the vas to dislodge the polymer or by reinjection 
with a dissolving agent. The technique was origi-
nally developed in India,30 and a related compound is 
currently undergoing animal trials in the USA under 
the brand name Vasalgel. Following successful trials in 
non-human primates,31 further preclinical studies are 
under way.
Adrenoreceptor antagonists
Transport of sperm from the epididymis along the 
vas is mediated by smooth muscle contractility. 
Alpha-1-adrenoreceptor antagonists, such as tamsu-
losin, inhibit this contractility, and patients treated with 
these drugs for other reasons demonstrate reduced 
sperm content in semen.32 The contraceptive potential 
of these drugs has been explored only in small studies, 
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at doses of 0.8 mg, but this had side effects including 
transient discomfort lasting up to 10 hours. At a lower 
dose of 0.4 mg, side effects were reduced, but higher 
numbers of functional sperm were found in seminal 
fluid. There is potential that this or a similar compound 
could be used as an ‘on-demand’ male contraceptive as 
the effect of these drugs is transient.
barrier methods
Barrier methods will, for the foreseeable future, have 
an important role in infection prevention. Novel mate-
rials and production methods are increasing the diver-
sity of condoms available on the market with an aim to 
improve sensation while retaining safety and efficacy. 
Funding from a charitable organisation has been used 
to develop a self-lubricating condom that may improve 
pleasure and reduce discomfort, as well as reduce fric-
tion-related damage to the condom.33
microchip delivery
Novel methods of delivery of existing compounds may 
be possible. Microchip technology to deliver proges-
togen-only contraception for women is currently in 
development and has been used for delivery of para-
thyroid hormone.34 This format would be a truly 
LARC method and could overcome the difficulties 
in dosing frequency for testosterone alone or with a 
progestogen.
WIll novel mAle methods meet the 
generAl prIncIples of contrAceptIve 
development?
There are five domains broadly sought after in a novel 
contraceptive method35:
1. Contraceptives must have high efficacy, both in con-
trolled settings and in real-world use.
2. The contraceptive effect must be reversible: while there 
may be some utility to alternative methods of permanent 
contraception, safe effective methods of achieving this 
already exist and the gap in the market is for true, on-de-
mand reversibility.
3. Speed of action: the time taken from initiating the con-
traceptive until the method offers protection from preg-
nancy should be as short as possible to prevent unintend-
ed pregnancy.
4. Ease of use: novel contraceptives should be simple to use, 
whether they are patient-initiated (pills and gels) or clini-
cian-initiated (injections and implants), with clear ‘missed 
pill’ rules. This also includes issues of accessibility.
5. Safety: side effects should be minimal to reduce dis-
continuation, particularly with regard to secondary sex 
characteristics, sexual function and sexual pleasure. Non-
contraceptive benefits should be maximised and should 
not be worse than no contraception.
It is clear that fulfilling all of these domains is closer 
than ever before for some of the approaches discussed 
above. Efficacy of currently studied methods looks to 
be high, with low rates of residual spermatogenesis 
and low rates of pregnancy. Likewise, reversibility 
following discontinuation appears complete and treat-
ment modalities are familiar and easy to use (injec-
tions, gels and pills). Speed of action is where this 
approach falls down slightly—hormonal methods 
currently being investigated require several weeks 
of use before they can be relied on, although this is 
similar to vasectomy. Male hormonal methods also 
appear to be largely safe, being based on steroids that 
have been used in large numbers of people over many 
years, without detriment to secondary sex character-
istics. Hormonal methods can have a negative effect 
on cholesterol, particularly decreases in high-density 
lipoprotein cholesterol, which may play a role in heart 
disease risk, but this must be interpreted with caution 
as it may largely reflect historical approaches based 
on high doses of testosterone, and risk of cardiovas-
cular disease is complex and multifactorial. There 
may be positive non-contraceptive benefits of these 
drugs in terms of prostate function, muscle mass and 
bone density that will not be understood until there 
are longer-term, population-level data, and the use of 
novel steroids may increase these benefits.
socIAl probAbIlItIes
Ample evidence exists to show that high proportions 
of men find the idea of a male contraceptive acceptable 
and that women would rely on their male partners to 
use a male contraceptive method.36
It is important to remember that many women rely 
on their male partner for contraception already—
approximately 54% of women in the UK use either 
male sterilisation, male condom or withdrawal method 
as their main method of contraception.37
Thus, men want to engage in reproductive health, 
but their current options are limited compared 
with the range of contraceptive choices available to 
women. Male hormonal contraceptive methods do not 
currently exist on the market anywhere globally and 
so we cannot base our assumptions on future use of 
these methods on how current methods are used. Men 
may be attracted to male hormonal contraceptives 
for non-contraceptive benefits, similar to the familiar 
non-contraceptive benefits of female hormonal 
methods, and this is an aspect that can potentially be 
‘engineered’ into methods based on novel steroids.
chAllenges for servIces
In the current research paradigm, male contracep-
tion development involves frequent semen analysis 
to confirm azoospermia/oligospermia prior to relying 
on the method as a contraceptive. During later phase 
studies and then as male contraceptives enter clin-
ical practice, the focus will need to shift from inten-
sive monitoring of sperm concentrations and more to 
general rules of use. However, semen analysis remains 
in routine clinical practice for confirming vasec-
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suppression may also be a possibility with several 
companies developing such technology in relation to 
infertility.38
summAry
More diverse methods of male contraceptives are 
needed to help meet the unmet contraceptive need 
of men and women everywhere. Research into these 
methods has been ongoing since the 1970s, but devel-
opment has been hindered by a wide range of factors: 
challenges for funding of male methods and lack of 
industry involvement, disbelief that there is a real 
need for novel male methods, slow development of 
novel testosterone preparations, and the underlying 
physiology whereby men produce millions of sperm 
per day rather than releasing one oocyte per month. 
Fortunately, we are closer than ever to new hormonal 
methods coming to the market, and while non-hor-
monal methods seem at present more distant they 
have the potential to make a major contribution in the 
future.
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